TET2

Summary

Gene Symbol: TET2
Description: tet methylcytosine dioxygenase 2
Alias: KIAA1546, MDS, methylcytosine dioxygenase TET2, tet oncogene family member 2
Species: human

Top Publications

  1. pmc Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies
    Omar Abdel-Wahab
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Blood 114:144-7. 2009
  2. doi Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission
    Olivier Nibourel
    Laboratoire d Hematologie, Centre Hospitalier Regional Universitaire de Lille, Boulevard du Professeur Leclercq, Lille Cedex, France
    Blood 116:1132-5. 2010
  3. ncbi TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23)
    R B Lorsbach
    Leukemia 17:637-41. 2003
  4. pmc TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis
    A Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 23:905-11. 2009
  5. pmc Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML.
    A Tefferi
    Leukemia 23:1343-5. 2009
  6. pmc Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms
    Anna M Jankowska
    Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, OH 44195, USA
    Blood 113:6403-10. 2009
  7. doi Mutation in TET2 in myeloid cancers
    Francois Delhommeau
    INSERM U790, Institut Gustave Roussy, Villejuif, France
    N Engl J Med 360:2289-301. 2009
  8. doi Acquired mutations in TET2 are common in myelodysplastic syndromes
    Saskia M C Langemeijer
    Department of Hematology and Central Hematology Laboratory, Radboud University Nijmegen Medical Centre and Nijmegen Centre for Molecular Life Sciences, Nijmegen, The Netherlands
    Nat Genet 41:838-42. 2009
  9. doi Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome
    Azim M Mohamedali
    Department of Haematological Medicine, King s College London School of Medicine, London, UK
    J Clin Oncol 27:4002-6. 2009
  10. doi Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms
    Cécile Saint-Martin
    Department of Genetics, Assistance Publique Hopitaux de Paris AP HP Groupe Hospitalier Pitié Salpétrière, Universite Pierre et Marie Curie, Paris, France
    Blood 114:1628-32. 2009

Research Grants

  1. REGULATION AND FUNCTION OF C AB1 NUCLEAR TYROSINE KINASE
    RICHARD VAN ETTEN; Fiscal Year: 2001
  2. Chemical modulators of Tet-family proteins
    Anjana Rao; Fiscal Year: 2010
  3. Anjana Rao; Fiscal Year: 2016
  4. Merav Socolovsky; Fiscal Year: 2016
  5. Anjana Rao; Fiscal Year: 2014
  6. Craig B Thompson; Fiscal Year: 2016
  7. Anjana Rao; Fiscal Year: 2015
  8. Reuben Kapur; Fiscal Year: 2016
  9. Gerd P Pfeifer; Fiscal Year: 2016
  10. Ann Mullally; Fiscal Year: 2015

Detail Information

Publications175 found, 100 shown here

  1. pmc Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies
    Omar Abdel-Wahab
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Blood 114:144-7. 2009
    ..Based on the recent identification of TET2 mutations, we evaluated the mutational status of TET1, TET2, and TET3 in myeloproliferative neoplasms (MPNs), ..
  2. doi Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission
    Olivier Nibourel
    Laboratoire d Hematologie, Centre Hospitalier Regional Universitaire de Lille, Boulevard du Professeur Leclercq, Lille Cedex, France
    Blood 116:1132-5. 2010
    Mutations of the ten eleven translocation 2 gene (TET2) have recently been reported in myelodysplastic syndrome and myeloproliferative neoplasms...
  3. ncbi TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23)
    R B Lorsbach
    Leukemia 17:637-41. 2003
  4. pmc TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis
    A Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 23:905-11. 2009
    High-throughput DNA sequence analysis was used to screen for TET2 mutations in bone marrow-derived DNA from 239 patients with BCR-ABL-negative myeloproliferative neoplasms (MPNs)...
  5. pmc Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML.
    A Tefferi
    Leukemia 23:1343-5. 2009
  6. pmc Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms
    Anna M Jankowska
    Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, OH 44195, USA
    Blood 113:6403-10. 2009
    ..We then investigated genes in the commonly affected area for mutations. When we sequenced TET2, we found homozygous and hemizygous mutations...
  7. doi Mutation in TET2 in myeloid cancers
    Francois Delhommeau
    INSERM U790, Institut Gustave Roussy, Villejuif, France
    N Engl J Med 360:2289-301. 2009
    ..The myelodysplastic syndromes and myeloproliferative disorders are associated with deregulated production of myeloid cells. The mechanisms underlying these disorders are not well defined...
  8. doi Acquired mutations in TET2 are common in myelodysplastic syndromes
    Saskia M C Langemeijer
    Department of Hematology and Central Hematology Laboratory, Radboud University Nijmegen Medical Centre and Nijmegen Centre for Molecular Life Sciences, Nijmegen, The Netherlands
    Nat Genet 41:838-42. 2009
    ..sequencing in 102 individuals with MDS and identified acquired deletions and missense and nonsense mutations in the TET2 gene in 26% of these individuals...
  9. doi Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome
    Azim M Mohamedali
    Department of Haematological Medicine, King s College London School of Medicine, London, UK
    J Clin Oncol 27:4002-6. 2009
    ..We investigated the sequence integrity of 4q24 candidate tumor suppressor gene TET2 in MDS patients with UPD on chromosome 4.
  10. doi Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms
    Cécile Saint-Martin
    Department of Genetics, Assistance Publique Hopitaux de Paris AP HP Groupe Hospitalier Pitié Salpétrière, Universite Pierre et Marie Curie, Paris, France
    Blood 114:1628-32. 2009
    ..A putative tumor suppressor gene, TET2, was recently implicated in MPN and myelodysplastic syndromes through the identification of acquired mutations ..
  11. doi Mutations of ASXL1 gene in myeloproliferative neoplasms.
    N Carbuccia
    Leukemia 23:2183-6. 2009
  12. doi Analyses of TET2 mutations in post-myeloproliferative neoplasm acute myeloid leukemias.
    L Couronné
    Leukemia 24:201-3. 2010
  13. pmc TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia
    Olivier Kosmider
    Hematology Department, Hôpital Cochin APHP, Paris, France
    Haematologica 94:1676-81. 2009
    Acquired somatic deletions and loss-of-function mutations in one or several codons of the TET2 (Ten-Eleven Translocation-2) gene were recently identified in hematopoietic cells from patients with myeloid malignancies, including ..
  14. pmc Mutations of JAK2 and TET2, but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosis.
    Johanna Flach
    Haematologica 95:518-9. 2010
  15. pmc Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia
    Hideki Muramatsu
    Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, OH 44195, USA
    Blood 115:1969-75. 2010
    ..In total, c-Cbl mutations were detected in 5 (10%) of 49 patients. No mutations were identified in Cbl-b and TET2. c-Cbl and RAS pathway mutations were mutually exclusive...
  16. doi Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms
    Franz X Schaub
    Department of Biomedicine, Experimental Hematology, University Hospital Basel, Hebelstr 20, 4031 Basel, Switzerland
    Blood 115:2003-7. 2010
    Somatic mutations in TET2 occur in patients with myeloproliferative neoplasms and other hematologic malignancies. It has been suggested that TET2 is a tumor suppressor gene and mutations in TET2 precede the acquisition of JAK2-V617F...
  17. doi The idic(X)(q13) in myeloid malignancies: breakpoint clustering in segmental duplications and association with TET2 mutations
    Kajsa Paulsson
    Department of Clinical Genetics, University and Regional Laboratories, Lund University Hospital, Lund University, Lund, Sweden
    Hum Mol Genet 19:1507-14. 2010
    ..partial uniparental disomies for 9p (one case) and 4q (two cases) associated with homozygous mutations of JAK2 and TET2, respectively...
  18. pmc Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations
    Hadrian Szpurka
    Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
    Leuk Res 34:969-73. 2010
    ..Based on the association of TET2/ASXL1 mutations with MDS/MPN we studied molecular pattern of these genes...
  19. pmc Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
    A Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 24:1128-38. 2010
    ..a number of novel mutations involving Janus kinase 2 (JAK2), Myeloproliferative Leukemia Virus (MPL), TET oncogene family member 2 (TET2), Additional Sex Combs-Like 1 (ASXL1), Casitas B-lineage lymphoma proto-oncogene (CBL), ..
  20. doi Chromosomal abnormalities in transformed Ph-negative myeloproliferative neoplasms are associated to the transformation subtype and independent of JAK2 and the TET2 mutations
    Florence Nguyen-Khac
    Hématologie biologique, Hopital Pitie Salpetriere, APHP, Paris, France
    Genes Chromosomes Cancer 49:919-27. 2010
    ..JAK2V617F and TET2 mutations were searched for in 40 and 32 patients, respectively. Significantly more -7/del(7q) (P = 0...
  21. doi Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1
    Alexander Kohlmann
    MLL Munich Leukemia Laboratory, Munchen, Germany
    J Clin Oncol 28:3858-65. 2010
    ..Thus far, data on a comprehensive cytogenetic or molecular genetic characterization are limited...
  22. doi Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value
    Alexander E Smith
    Department of Hematologic Medicine, King s College London School of Medicine, London, United Kingdom
    Blood 116:3923-32. 2010
    Mutations in the TET2 gene are frequent in myeloid disease, although their biologic and prognostic significance remains unclear...
  23. doi ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia
    Véronique Gelsi-Boyer
    Laboratoire d Oncologie Moleculaire, Centre de Recherche en Cancerologie de Marseille, UMR891 Inserm, Institut Paoli Calmettes, Universite de la Mediterranee Aix Marseille II, Marseille, France
    Br J Haematol 151:365-75. 2010
    ..and sequencing of 13 candidate genes including ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, PTPN11, RUNX1, TET2 and WT1...
  24. pmc Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2
    Myunggon Ko
    Department of Pathology, Harvard Medical School, Immune Disease Institute and Program in Cellular and Molecular Medicine, Children s Hospital Boston, Boston, Massachusetts 02115, USA
    Nature 468:839-43. 2010
    b>TET2 is a close relative of TET1, an enzyme that converts 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) in DNA...
  25. pmc Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation
    Maria E Figueroa
    Weill Cornell Medical College, New York, NY 10065, USA
    Cancer Cell 18:553-67. 2010
    ..In the AML cohort, IDH1/2 mutations were mutually exclusive with mutations in the α-ketoglutarate-dependent enzyme TET2, and TET2 loss-of-function mutations were associated with similar epigenetic defects as IDH1/2 mutants...
  26. pmc Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases
    Wei Xu
    State Key Laboratory of Genetic Engineering, School of Life Sciences, Shanghai Medical School, Fudan University, Shanghai 20032, China
    Cancer Cell 19:17-30. 2011
    ..Hence, tumor-derived IDH1 and IDH2 mutations reduce α-KG and accumulate an α-KG antagonist, 2-HG, leading to genome-wide histone and DNA methylation alterations...
  27. doi Genetics of the myeloproliferative neoplasms
    Omar Abdel-Wahab
    Human Oncology and Pathogenesis Program and Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Curr Opin Hematol 18:117-23. 2011
    ..The purpose of this review is to outline the most recent discoveries of the genetic alterations found in patients with MPNs...
  28. doi TET2 promoter methylation in low-grade diffuse gliomas lacking IDH1/2 mutations
    Young Ho Kim
    International Agency for Research on Cancer, Lyon, France
    J Clin Pathol 64:850-2. 2011
    Miscoding mutations of the TET2 gene, which encodes the α-ketoglutarate-dependent enzyme that catalyses the conversion of 5-methylcytosine to 5-hydroxymethylcytosine, thus producing DNA demethylation, have been detected in 10-25% of ..
  29. pmc Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation
    Kelly Moran-Crusio
    Department of Pathology, NYU Cancer Institute, New York University School of Medicine, NY 10016, USA
    Cancer Cell 20:11-24. 2011
    Somatic loss-of-function mutations in the ten-eleven translocation 2 (TET2) gene occur in a significant proportion of patients with myeloid malignancies...
  30. doi TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis
    Cyril Quivoron
    INSERM, U, Villejuif, France
    Cancer Cell 20:25-38. 2011
    ..We report that inactivation of Tet2 in mouse perturbs both early and late steps of hematopoiesis including myeloid and lymphoid differentiation in a ..
  31. doi Landscape of TET2 mutations in acute myeloid leukemia
    S Weissmann
    MLL Munich Leukemia Laboratory, Munich, Germany
    Leukemia 26:934-42. 2012
    We investigated ten-eleven translocation 2 (TET2) mutations in acute myeloid leukemia (AML), their correlation with other gene mutations and prognostic value. By deep-sequencing, 131 somatic TET2 mutations were identified in 87/318 (27...
  32. pmc Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis
    Fabiola Traina
    Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States of America
    PLoS ONE 7:e43090. 2012
    ..areas of loss of heterozygosity and bidirectional sequencing was performed to evaluate the mutational status of TET2, DNMT3A, ASXL1, EZH2, IDH1/IDH2 and the CBL gene family...
  33. doi In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells
    Erinn Soucie
    Inserm U1068, Centre de Recherche en Cancerologie de Marseille, centre de référence des mastocytoses, Institut Paoli Calmettes, Universite de la Mediterranee, Marseille, France
    Blood 120:4846-9. 2012
    ..number of aggressive and nonaggressive cases of systemic mastocytosis, that in contrast to the oncogenic KITD816V, TET2 mutation statistically associates with aggressive forms of the disease...
  34. pmc TET2 promotes histone O-GlcNAcylation during gene transcription
    Qiang Chen
    Division of Molecular Medicine and Genetics, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
    Nature 493:561-4. 2013
    Ten eleven translocation (TET) enzymes, including TET1, TET2 and TET3, convert 5-methylcytosine to 5-hydroxymethylcytosine and regulate gene transcription...
  35. pmc TET2 and TET3 regulate GlcNAcylation and H3K4 methylation through OGT and SET1/COMPASS
    Rachel Deplus
    Laboratory of Cancer Epigenetics, Faculty of Medicine, Universite Libre de Bruxelles, Brussels, Belgium
    EMBO J 32:645-55. 2013
    ..has linked TET1 function to epigenetic repression complexes, yet mechanistic information, especially for the TET2 and TET3 proteins, remains limited...
  36. pmc Genome-wide profiling identifies a DNA methylation signature that associates with TET2 mutations in diffuse large B-cell lymphoma
    Fazila Asmar
    Haematologica 98:1912-20. 2013
    ..Clonal analysis of the hematopoetic stem cell compartment suggests that TET2 mutations can be early events in hematologic cancers and recent investigations have shown TET2 mutations in diffuse ..
  37. doi Crystal structure of TET2-DNA complex: insight into TET-mediated 5mC oxidation
    Lulu Hu
    Fudan University Shanghai Cancer Center, Department of Oncology and Institute of Biomedical Sciences, Shanghai Medical College of Fudan University, Shanghai 200032, China State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai 200433, China
    Cell 155:1545-55. 2013
    ..Mutations of TET2 are frequently observed in myeloid malignance...
  38. pmc Differential regulation of the ten-eleven translocation (TET) family of dioxygenases by O-linked β-N-acetylglucosamine transferase (OGT)
    Qiao Zhang
    From the Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai 200241, China and
    J Biol Chem 289:5986-96. 2014
    ..Although TET1 and TET2 also interact with and can be O-GlcNAcylated by OGT, neither their subcellular localization nor their enzymatic ..
  39. doi TET2 deficiency inhibits mesoderm and hematopoietic differentiation in human embryonic stem cells
    Thierry Langlois
    Institut National de la Sante et de la Recherche Medicale, UMR 1009, Laboratory of Excellence GR Ex, 114 rue Edouard Vaillant, Villejuif, Paris, France Institut Gustave Roussy, Villejuif, Paris, France Université Paris Sud 11, Orsay, France
    Stem Cells 32:2084-97. 2014
    Ten-eleven-translocation 2 (TET2) belongs to the TET protein family that catalyzes the conversion of 5-methylcytosine into 5-hydroxymethylcytosine and plays a central role in normal and malignant adult hematopoiesis...
  40. pmc Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates
    A Tefferi
    Divisions of Hematology and Hematopathology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 23:900-4. 2009
    TET2 (TET oncogene family member 2) is a candidate tumor suppressor gene located at chromosome 4q24, and was recently reported to be mutated in approximately 14% of patients with JAK2V617F-positive myeloproliferative neoplasms...
  41. doi TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs)
    Olivier Kosmider
    Assistance Publique Hopitaux de Paris AP HP, Service d Hematologie Biologique, Hôpital Cochin Hôtel Dieu, Paris, France
    Blood 114:3285-91. 2009
    ..of myelodysplastic syndromes (MDS) remain poorly characterized, but mutations of the ten-eleven translocation 2 (TET2) gene are frequently observed. In the present work, we evaluated the prognostic impact of TET2 mutations in MDS...
  42. doi Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics
    Ayalew Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Nat Rev Clin Oncol 6:627-37. 2009
    ..Additional MPN-associated molecular markers include mutations of JAK2, MPL, TET2 and KIT...
  43. ncbi [Mutation of tet2 gene and malignant blood disease]
    Xi Feng Qian
    Department of Hematology, Wuxi People Hospital, Nanjing Medical University, Wuxi 214000, Jiangsu Province, China
    Zhongguo Shi Yan Xue Ye Xue Za Zhi 18:1096-100. 2010
    b>Tet2 (the 2nd member of tet oncogene family) is a newly discovered antioncogene on the chromosome 4q24 of the patient with malignant myeloma, which has a potential for functional deletion...
  44. ncbi The molecular pathogenesis of myelodysplastic syndromes
    Matthew S Davids
    Department of Hematologic Malignancies, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Cancer Biol Ther 10:309-19. 2010
    ..Several genetic abnormalities, including mutations in RUNX1 (AML1), TET2, ASXL1 and TP53, have been discovered in a substantial fraction of MDS cases; genes rearranged or mutated less ..
  45. pmc Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification
    Shinsuke Ito
    Howard Hughes Medical Institute
    Nature 466:1129-33. 2010
    ..Here we extend this study by demonstrating that all three mouse Tet proteins (Tet1, Tet2 and Tet3) can also catalyse a similar reaction...
  46. pmc Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias
    Omar Abdel-Wahab
    Human Oncology and Pathogenesis Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer Res 70:447-52. 2010
    ..Frequent mutations were identified in TET2 (26.3%), ASXL1 (19.3%), IDH1 (9.5%), and JAK2 (36...
  47. doi Methylation of TET2, CBL and CEBPA in Ph-negative myeloproliferative neoplasms
    C S Chim
    Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong
    J Clin Pathol 63:942-6. 2010
    A loss-of-function mutation of TET2, CBL and CEBPA has been implicated in the pathogenesis or leukaemic transformation of myeloproliferative neoplasm...
  48. doi Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm
    Philip A Beer
    Department of Haematology, Cambridge Institute for Medical Research, Cambridge, UK
    Blood 115:2891-900. 2010
    ..A search for additional mutations identified alterations of RUNX1, WT1, TP53, CBL, NRAS, and TET2, without significant differences between JAK2-mutant and wild-type leukemias...
  49. doi Significance of JAK2 and TET2 mutations in myelodysplastic syndromes
    Eva Hellstrom-Lindberg
    Karolinska Institutet, Department of Medicine, Division of Hematology, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Blood Rev 24:83-90. 2010
    ..The identification of JAK2 and MPL mutations, and more recently TET2, CBL and ASXL-1 mutations in these disorders provide a basis for increased understanding of disease biology and ..
  50. doi The lower risk MDS patient at risk of rapid progression
    Moshe Mittelman
    Department of Medicine, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel
    Leuk Res 34:1551-5. 2010
    ..that methylation of p15 INK4b and of CTNNA1 (in 5q-), high level of methylation of other genes, absence of the TET2 mutation, down regulation of the lymphoid enhancer binding factor 1 (LEF1), mutation of the polycomb-associated ..
  51. doi LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations
    A Pardanani
    Department of Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 24:1713-8. 2010
    ..LNK mutations were not detected in 78 additional patients with chronic-phase MPN enriched for TET2, IDH, JAK2V617F, or MPL-mutated cases...
  52. ncbi Identification of human candidate genes for male infertility by digital differential display
    C Olesen
    Department of Medical Genetics, Institute of Medical Biochemistry and Genetics, University of Copenhagen, Blegdamsvej 3, DK 2200 Copenhagen N, Denmark
    Mol Hum Reprod 7:11-20. 2001
    ..Interestingly, the two tesis expressed-only transcripts, TET1 and TET2, mapped to chromosomal regions where seven and six translocation breakpoints have been reported in infertile males ..
  53. doi Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia
    Véronique Gelsi-Boyer
    Centre de Recherche en Cancerologie de Marseille, Département d Oncologie Moléculaire, UMR891 Inserm, Institut Paoli Calmettes, France
    Br J Haematol 145:788-800. 2009
    ..g. ASXL1, ASXL2, UTX, CXXC4, CXXC5, TET2, TET3). To validate some of these candidates we studied the sequence of ASXL1...
  54. pmc Copy neutral loss of heterozygosity: a novel chromosomal lesion in myeloid malignancies
    Christine O'Keefe
    Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Blood 115:2731-9. 2010
    ..regions and have led to the discovery of tumor suppressor genes, including c-CBL and family members, as well as TET2. Investigations into the underlying mechanisms generating CN-LOH have great promise for elucidating general cancer ..
  55. doi JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms
    Stephen T Oh
    Division of Hematology, Stanford Cancer Center, 875 Blake Wilbur Drive, Room 2324, Stanford, CA 94305 5821, USA
    Expert Rev Hematol 3:323-37. 2010
    ..Mutations in the TET2 gene have been identified in both JAK2 V617F-positive and -negative MPNs and other myeloid neoplasms, but their ..
  56. doi Mechanisms of mutations in myeloproliferative neoplasms
    Ross L Levine
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Best Pract Res Clin Haematol 22:489-94. 2009
    ..mutation? Single nucleotide polymorphisms at various loci and somatic mutations, such as those in MPLW515L/K, TET2 and in exon 12 of JAK2, may also contribute to the pathogenesis of these MPNs...
  57. doi Molecular aspects of myeloproliferative neoplasms
    Francois Delhommeau
    INSERM, U1009, Institut Gustave Roussy, Universite Paris Sud, 39 rue Camille Desmoulins, 94805 Villejuif, France
    Int J Hematol 91:165-73. 2010
    ..There are likely additional somatic genetic factors important for the MPN phenotype like the recently described TET2, ASXL1, and CBL mutations...
  58. doi Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial
    Thorsten Braun
    Hopital Avicenne, Assistance Publique Hopitaux de Paris AP HP, Hématologie Clinique, University Paris XIII, Bobigny, France
    Blood 118:3824-31. 2011
    ..With a median follow-up of 23 months, overall survival was 48% at 2 years. Mutations in ASXL1, TET2, AML1, NRAS, KRAS, CBL, FLT3, and janus kinase 2 (JAK2) genes, and hypermethylation of the promoter of the tumor ..
  59. doi TET2 is essential for survival and hematopoietic stem cell homeostasis
    K Shide
    Department of Gastroenterology and Hematology, Faculty of Medicine, Miyazaki University, Kiyotake, Miyazaki, Japan
    Leukemia 26:2216-23. 2012
    Ten-Eleven-Translocation 2 (TET2) is an enzyme that catalyzes the conversion of 5-methylcytosine into 5-hydroxymethylcytosine (5-hmC) and thereby alters the epigenetic state of DNA; somatic loss-of-function mutations of TET2 are ..
  60. pmc SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML)
    Manja Meggendorfer
    MLL Munich Leukemia Laboratory, Munich, Germany
    Blood 120:3080-8. 2012
    ..In addition, ASXL1, CBL, EZH2, JAK2V617F, KRAS, NRAS, RUNX1, and TET2 mutations were investigated in subcohorts...
  61. pmc Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo
    Omar Abdel-Wahab
    Human Oncology and Pathogenesis Program, 2 Leukemia Service, 3 Gerstner Sloan Kettering Graduate School of Biomedical Sciences, and 4 Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065
    J Exp Med 210:2641-59. 2013
    ..Asxl1 deletion reduces hematopoietic stem cell self-renewal, which is restored by concomitant deletion of Tet2, a gene commonly co-mutated with ASXL1 in MDS patients...
  62. pmc Synergistic mechanisms of DNA demethylation during transition to ground-state pluripotency
    Jamie A Hackett
    Wellcome Trust Cancer Research UK Gurdon Institute, University of Cambridge, Cambridge CB2 1QN, UK Wellcome Trust MRC Stem Cell Institute, University of Cambridge, Cambridge CB2 1QR, UK Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge CB2 3EG, UK
    Stem Cell Reports 1:518-31. 2013
    ..Mechanistically, repression of de novo methylases by PRDM14 drives DNA demethylation at slow kinetics, whereas TET1/TET2-mediated 5hmC conversion enhances both the rate and extent of hypomethylation...
  63. pmc Genetics of myeloproliferative neoplasms
    Aaron D Viny
    From the Human Oncology and Pathogenesis Program and Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY
    Cancer J 20:61-5. 2014
    ..Mutations in the de novo DNA methylation protein, DNMT3A, demethylation machinery, TET2 and related IDH1/2 production of oncometabolite 2-hydroxygluterate, and polycomb complex proteins EZH2 and ASXL1 ..
  64. doi Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes
    Raphael Itzykson
    Hematology Department, Hopital Saint Louis, Assistance Publique Hopitaux de Paris AP HP, France Université Paris 7, France INSERM Unit U944, Hopital St Louis, Paris, France
    Best Pract Res Clin Haematol 26:355-64. 2013
    ..e. cytokine signaling (RAS genes), DNA methylation, (TET2, IDH1/2, DNMT3a genes) histone modifications (ASXL1 and EZH2 genes), and spliceosome (SF3B1 and SRSF2 genes) along ..
  65. pmc 5-azacytidine improves the osteogenic differentiation potential of aged human adipose-derived mesenchymal stem cells by DNA demethylation
    Xueying Yan
    Siegfried Weller Institute for Trauma Research, BG Trauma Center, Eberhard Karls University Tubingen, Tubingen, Germany
    PLoS ONE 9:e90846. 2014
    ..activity and matrix mineralization was associated with an increased presence of 5 hmC as well as with an increased TET2 and TET3 gene expression...
  66. doi Role of genotype-based approach in the clinical management of adult acute myeloid leukemia with normal cytogenetics
    Antonia Cagnetta
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA Department of Hematology and Oncology, I R C C S A O U San Martino IST, Genoa, Italy Electronic address
    Leuk Res 38:649-59. 2014
    ..has recently shown the recurrence of genomic aberrations in this category (mutations of FLT3, CEBPA, NPM1, RUNX1, TET2, IDH1/2, DNMT3A, ASXL1, MLL and WT1) thus revealing its marked genomic heterogeneity...
  67. doi [Myelodysplastic syndromes]
    F Thol
    Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation, Medizinische Hochschule Hannover, Carl Neuberg Str 1, 30625, Hannover, Deutschland
    Internist (Berl) 56:364-73. 2015
    ..Genes of the splicing machinery as well as genes involved in epigenetic regulation (e.g. ASXL1 and TET2) are most frequently mutated in MDS. Therapy is selected based on the patient risk profile (IPSS)...
  68. doi Genetic alterations of DNA methylation machinery in human diseases
    Tewfik Hamidi
    Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Science Park Research Division, 1808 Park Road 1C, P O Box 389, Smithville, TX 78957, USA
    Epigenomics 7:247-65. 2015
    ..DNMT3B) and 'demethylating' proteins, including the ten-eleven translocation (TET) family of dioxygenases (TET1, TET2 and TET3)...
  69. doi [TET2 as a gatekeeper for hematologic malignancies]
    Hideharu Muto
    Department of Hematology, Faculty of Medicine, University of Tsukuba
    Rinsho Ketsueki 56:651-6. 2015
    ..Most notably, TET2 mutations have frequently been identified in myeloid malignancies, such as myelodysplastic syndromes (MDS), ..
  70. pmc 5-hydroxymethylation of the EBV genome regulates the latent to lytic switch
    Coral K Wille
    Department of Medical Microbiology and Immunology, Wisconsin Institutes for Medical Research WIMR II, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705
    Proc Natl Acad Sci U S A 112:E7257-65. 2015
    ..Decreased 5-hydroxymethylation of cellular and viral genes may contribute to NPC formation. ..
  71. doi Vitamin C Facilitates Demethylation of the Foxp3 Enhancer in a Tet-Dependent Manner
    Varun Sasidharan Nair
    Department of Pathology, Hallym University College of Medicine, Chuncheon, Gangwon do 200 702, Korea
    J Immunol 196:2119-31. 2016
    ..In this study, we found that vitamin C induces CNS2 demethylation in Tregs in a ten-eleven-translocation 2 (Tet2)-dependent manner...
  72. doi Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing
    Mrinal M Patnaik
    Division of Hematology, Mayo Clinic, Rochester, Minnesota
    Am J Hematol 91:492-8. 2016
    ..had ≥1 mutations; common mutations being: SF3B1 85%, JAK2V617F 33%, ASXL1 29%, DNMT3A 13%, SETBP1 13% and TET2 10%. In a multivariable survival analysis (n = 82), anemia (P = 0.02) [HB< 10 gm/dl: HR 2.3, 95% CI 1...
  73. doi Roles of IDH1/2 and TET2 mutations in myeloid disorders
    Satoshi Inoue
    The Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, Ontario Cancer Institute, University Health Network, 610 University Avenue, Toronto, ON, M5G 2M9, Canada
    Int J Hematol 103:627-33. 2016
    ..enzymes isocitrate dehydrogenase (IDH) 1 and 2, and the methylcytosine dioxygenase 'ten-eleven translocation 2' (TET2), are common in human myeloid malignancies and drivers of these disorders but the underlying mechanisms remain ..
  74. pmc Immune Regulator MCPIP1 Modulates TET Expression during Early Neocortical Development
    Huihui Jiang
    State Key Laboratory of Stem Cells and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China
    Stem Cell Reports 7:439-53. 2016
    ..MCPIP1 is important for maintenance of the NPC pool. Notably, we demonstrate that MCPIP1 reduces TET (TET1/TET2/TET3) levels and then decreases 5-hydroxymethylcytosine levels...
  75. doi DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions.
    Manuel Buscarlet
    Blood 130:753-762. 2017
    ..We report a higher overall prevalence of driver mutations (13.7%), which occurred mostly (93%) in DNMT3A or TET2 and were highly age-correlated. Mutation in these 2 genes had some distinctive effects on end points...
  76. ncbi Identification and characterization of human CXXC10 gene in silico
    Masuko Katoh
    M and M Medical BioInformatics, Narashino 275 0022, Japan
    Int J Oncol 25:1193-9. 2004
    ..CXXC10-2 (937 aa) was homologous to CXXC6, and KIAA1546. Complete coding sequence of KIAA1546 cDNA was determined by assembling BF900449 EST, IMAGE3536481 partial cDNA, ..
  77. pmc Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
    Heiko Becker
    Division of Hematology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Haematologica 96:1488-95. 2011
    ..To validate this finding, we investigated pretreatment features and outcome associated with rs16754 in a large cohort of patients with cytogenetically normal acute myeloid leukemia...
  78. doi TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics
    Wen Chien Chou
    Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan
    Blood 118:3803-10. 2011
    The studies concerning clinical implications of TET2 mutation in patients with primary acute myeloid leukemia (AML) are scarce. We analyzed TET2 mutation in 486 adult patients with primary AML. TET2 mutation occurred in 13...
  79. ncbi [Detection of the JAK2 gene mutation in familial myeloproliferative neoplasm and its clinical significance]
    Yong Min Zhang
    Department of Hematology, Nanfang Hospital of Southern Medical Univesity, Guangzhou 510515, China
    Zhonghua Xue Ye Xue Za Zhi 33:103-7. 2012
    To comprehend the abnormalities of JAK2, c-mp, EPOR, MPW515L/K and TET2 genes in patients with familial myeloproliferative neoplasm (MPN) and their relatives, and to explore mechanism of MPN pathogenesis.
  80. pmc Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes
    Mikkael A Sekeres
    Leukemia Program, Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Ave, Cleveland, OH 44195, USA
    Blood 120:4945-51. 2012
    ..6 months for the entire cohort (range, 3-55). TET2/DNMT3A/IDH1/2 mutational status was associated with response in a limited number of patients...
  81. doi Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm
    J Menezes
    Molecular Cytogenetics Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre CNIO, Madrid, Spain
    Leukemia 28:823-9. 2014
    ..Target sequencing identified 29 recurring genes, ranging in prevalence from 36% for previously known genes, such as TET2, to 12-16% for newly identified genes, such as IKZF3 or ZEB2...
  82. pmc SRSF2-p95 hotspot mutation is highly associated with advanced forms of mastocytosis and mutations in epigenetic regulator genes
    Katia Hanssens
    Haematologica 99:830-5. 2014
    ..KIT, SRSF2-P95 and TET2 mutations were by far the most frequent, detected in 81%, 24% and 21% of patients, respectively...
  83. pmc TET2 plays an essential role in erythropoiesis by regulating lineage-specific genes via DNA oxidative demethylation in a zebrafish model
    Liang Ge
    College of Life Sciences, Zhejiang University, Hangzhou, People s Republic of China Key Laboratory for Cell and Gene Engineering of Zhejiang Province, Hangzhou, People s Republic of China
    Mol Cell Biol 34:989-1002. 2014
    ..TETs mediate the conversion of 5mC to hydroxymethylcytosine (5hmC) in zebrafish embryos, and the deletion of TET2 inhibits erythropoiesis by suppressing the expression of the scl, gata-1, and cmyb genes...
  84. doi The molecular pathogenesis of the myelodysplastic syndromes
    Andrea Pellagatti
    Leukaemia and Lymphoma Research Molecular Haematology Unit, Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK
    Eur J Haematol 95:3-15. 2015
    ..in genes involved in RNA splicing (including SF3B1, SRSF2, U2AF1, and ZRSR2) and epigenetic modification (including TET2, ASXL1, and DNMT3A)...
  85. pmc Hydroxymethylcytosine and demethylation of the γ-globin gene promoter during erythroid differentiation
    Maria Armila Ruiz
    a Jesse Brown VA Medical Center Chicago, IL, USA
    Epigenetics 10:397-407. 2015
    ..The Tet2 and Tet3 dioxygenases that catalyze formation of 5 hmC are expressed during early stages of erythroid ..
  86. pmc Mutational Hotspot of TET2, IDH1, IDH2, SRSF2, SF3B1, KRAS, and NRAS from Human Systemic Mastocytosis Are Not Conserved in Canine Mast Cell Tumors
    Eleonora Zorzan
    Department of Comparative Biomedicine and Food Science, University of Padua, Legnaro, Padua, Italy
    PLoS ONE 10:e0142450. 2015
    ..In the present study, the mutational profile of the Tet methylcytosine dioxygenase 2 (TET2), the isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2), the serine/arginine-rich splicing factor 2 (SRSF2), the ..
  87. pmc Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia
    M M Patnaik
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
    Blood Cancer J 6:e385. 2016
    Mutations involving epigenetic regulators (TET2~60% and ASXL1~40%) and splicing components (SRSF2~50%) are frequent in chronic myelomonocytic leukemia (CMML)...
  88. doi Genetic alterations and their clinical implications in older patients with acute myeloid leukemia
    C H Tsai
    Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
    Leukemia 30:1485-92. 2016
    ..Compared with the younger patients, the elderly had significantly higher incidences of PTPN11, NPM1, RUNX1, ASXL1, TET2, DNMT3A and TP53 mutations but a lower frequency of WT1 mutations...
  89. pmc Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation
    Esther A Obeng
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA Division of Hematology Oncology, Department of Medicine, Boston Children s Hospital, Boston, MA 02115, USA Division of Hematology, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Cancer Cell 30:404-17. 2016
    ..b>Tet2 loss cooperates with Sf3b1(K700E) to cause a more severe erythroid and LT-HSC phenotype...
  90. pmc The cysteine-rich domain of TET2 binds preferentially to mono- and dimethylated histone H3K36
    Kazuyuki Yamagata
    Division of Newborn Medicine, Children s Hospital Boston
    J Biochem . 2017
    Missense mutations in Ten-eleven translocation 2 (TET2) gene are frequently found in leukaemia patients...
  91. doi Decreased 5-hydroxymethylcytosine levels are associated with TET2 mutation and unfavorable overall survival in myelodysplastic syndromes
    Xiaoliu Liu
    Division of Hematology, Institute of Molecular Hematology, The Second Xiang Ya Hospital, Central South University, Changsha, Hunan, P R of China
    Leuk Lymphoma 54:2466-73. 2013
    The clinical significance and mechanisms of TET2 are not well defined in myeloid malignancies. We detected TET2 mutations and assayed its catalyzing conversion product 5-hydroxymethylcytosine (5-hmC) in 61 Chinese patients with MDS...
  92. doi The CpG island methylator phenotype: what's in a name?
    Laura A E Hughes
    Authors Affiliations Departments of Epidemiology and Pathology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht Department of Surgery, Orbis Medical Center, Sittard Geleen Department of Pathology, Leiden University Medical Center, Leiden Department of Neurology, Erasmus University Medical Center, Erasmus University, Rotterdam, the Netherlands Department of Mathematical Modeling, Statistics and Bioinformatics, Ghent University, Ghent, Belgium and The Johns Hopkins University School of Medicine, Baltimore, Maryland
    Cancer Res 73:5858-68. 2013
    ..and IDH2 mutations, and loss-of-function mutations in ten-eleven translocation (TET) methylcytosine dioxygenase-2 (TET2) associated with a hypermethylation phenotype, are also found in multiple enchondromas of patients with Ollier ..
  93. pmc Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes
    Marta Fernandez-Mercado
    Haematologica 98:1856-64. 2013
    ..Fifty-two percent of mutations identified were in genes involved in epigenetic regulation (ASXL1, TET2, DNMT3A and JAK2)...
  94. doi Comprehensive mutational profiling in advanced systemic mastocytosis
    Juliana Schwaab
    III Medizinische Klinik, Hämatologie und Onkologie, Universitatsmedizin Mannheim, Mannheim, Germany
    Blood 122:2460-6. 2013
    ..SF3B1, SETBP1, U2AF1 at mutational hotspot regions, and analyzed complete coding regions of EZH2, ETV6, RUNX1, and TET2. We identified additional molecular aberrations in 24/27 (89%) patients with advanced SM (SM-AHNMD, 5/5; aggressive ..
  95. pmc The genetic basis of myelodysplasia and its clinical relevance
    Mario Cazzola
    Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy and
    Blood 122:4021-34. 2013
    ..Driver mutant genes include those of RNA splicing (SF3B1, SRSF2, U2AF1, and ZRSR2), DNA methylation (TET2, DNMT3A, and IDH1/2), chromatin modification (ASXL1 and EZH2), transcription regulation (RUNX1), DNA repair (TP53), ..
  96. doi Focus on the epigenome in the myeloproliferative neoplasms
    Eunhee Kim
    1Human Oncology and Pathogenesis Program and
    Hematology Am Soc Hematol Educ Program 2013:538-44. 2013
    ..modifiers have been described in patients with MPNs, including mutations in ASXL1, DNMT3A, EZH2, IDH1, IDH2, and TET2. Moreover, the mutant JAK2 itself has been shown recently to affect histone posttranslational modifications ..
  97. pmc Feature-based classification of amino acid substitutions outside conserved functional protein domains
    Branislava Gemovic
    Centre for Multidisciplinary Research and Engineering, Vinca Institute of Nuclear Sciences, University of Belgrade, 12 14 Mihajla Petrovica Alasa, 11001 Belgrade, Serbia
    ScientificWorldJournal 2013:948617. 2013
    ..and mutations associated with myeloid malignancies from epigenetic regulators ASXL1, DNMT3A, EZH2, and TET2. PolyPhen-2 and SIFT had significantly lower accuracies in predicting the effects of amino acid substitutions ..
  98. pmc Probing DNA by 2-OG-dependent dioxygenase
    Chi Lin Tsai
    Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA
    Cell 155:1448-50. 2013
    ..Hu et al. now determine the crystal structure of the TET2 catalytic domain bound to DNA, shedding light on 5mC-DNA substrate recognition and the catalytic mechanism of 5mC ..
  99. ncbi A novel peptide defined through phage display for therapeutic protein and vector neuronal targeting
    James K Liu
    Department of Neuroscience and Center for Neurological Restoration, NB2 126, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Neurobiol Dis 19:407-18. 2005
    ..Phage ELISAs revealed increases in G(T1b) binding for the Tet1 and Tet2 phage clones when compared to peptideless phage (PLP)...
  100. doi Mutations and prognosis in primary myelofibrosis
    A M Vannucchi
    Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
    Leukemia 27:1861-9. 2013
    ..from the European cohort, collected at time of diagnosis, were analyzed for mutations in ASXL1, SRSF2, EZH2, TET2, DNMT3A, CBL, IDH1, IDH2, MPL and JAK2...

Research Grants35

  1. REGULATION AND FUNCTION OF C AB1 NUCLEAR TYROSINE KINASE
    RICHARD VAN ETTEN; Fiscal Year: 2001
    ..Finally, primary abl-/- fibroblasts (before and after rescue with selected abl constructs) will be used to assess the role of c-abl in growth arrest induced by DNA damage. ..
  2. Chemical modulators of Tet-family proteins
    Anjana Rao; Fiscal Year: 2010
    ..We have recently discovered that the TET proteins TET1, TET2 and TET3 constitute a new family of 2-oxoglutarate (2OG)- and Fe(II)-dependent dioxygenases that catalyse ..
  3. Anjana Rao; Fiscal Year: 2016
    ..We recently discovered that the TET proteins TET1, TET2 and TET3 constitute a new family of dioxygenases that utilize molecular oxygen and the cofactors Fe(II) and 2-..
  4. Merav Socolovsky; Fiscal Year: 2016
    ..following three aims: Aim 1: Determine whether 5mC in erythroid genomic DNA is subject to oxidation by the enzyme Tet2, resulting in replication-dependent, Dnmt1-resistant global demethylation Aim 2: Determine the role of the Cyclin-..
  5. Anjana Rao; Fiscal Year: 2014
    ..We recently discovered that the TET proteins TET1, TET2 and TET3 constitute a new family of 2-oxoglutarate (2OG)- and Fe(II)-dependent oxygenases, that convert 5- ..
  6. Craig B Thompson; Fiscal Year: 2016
    ..R132 or IDH2 R172 versus IDH2 R140 mutations in leukemic prognosis;2) Compare the effects of IDH mutation versus TET2 mutation on histone methylation status and gene expression in AML;3) Determine if the manipulation of 2HG levels ..
  7. Anjana Rao; Fiscal Year: 2015
    ..We recently discovered that the TET proteins TET1, TET2 and TET3 constitute a new family of 1-ketoglutarate (1KG)- and Fe(II)-dependent dioxygenases that alter DNA ..
  8. Reuben Kapur; Fiscal Year: 2016
    ..Recent studies in patients with mastocytosis have shown the presence of Tet2 mutations in ~30% patients...
  9. Gerd P Pfeifer; Fiscal Year: 2016
    ..myelodysplastic syndrome (MDS), because this malignancy often is characterized by mutations in one of the TET genes, TET2. The third Aim will focus on functional studies of TET and TET-associated proteins and their aberrations in cancer.
  10. Ann Mullally; Fiscal Year: 2015
    ..are to (1) perform detailed functional characterization of Jak2V617F mutant HSCs;(2) investigate the effect of Tet2 loss on Jak2V617F mediated MPN and (3) determine molecular dependencies and co-operating pathways in Jak2V617F ..
  11. The role of TET oncogene family member 2 in myeloproliferative neoplasms
    Kristy L Wolniak; Fiscal Year: 2012
    ..Recently, mutations in a previously undefined gene, TET oncogene family member-2 (TET2) has been identified in a subset of patients with MPNs, as well as patients with other diseases of the blood...
  12. Mingjiang Xu; Fiscal Year: 2016
    DESCRIPTION (provided by applicant): TET2 gene is mutated and/or deleted with high frequencies in multiple forms of myeloid malignancies including CMML, MDS, MPN and AML...
  13. Louis C Dore; Fiscal Year: 2015
    ..Additionally, we will identify genome-wide occupancy maps for TET1 and TET2, as well as thymine DNA glycosylase, the enzyme responsible for removing 5fC and 5caC from DNA to allow for ..
  14. KATHLEEN ANN MARTIN; Fiscal Year: 2016
    ..We have discovered distinct roles for Akt1 and Akt2 in the response to vascular injury. We have also identified TET2 and LMO7 as novel mTORC1-regulated proteins that modulate VSMC phenotype...
  15. Engineering Tet for single-base resolution sequencing of 5hmC
    Delin Ren; Fiscal Year: 2013
    ..Professor Chuan He's group at the University of Chicago, we plan to systematically engineer mouse Tet1 and Tet2 to significantly improve the stability and activity of these enzymes for large-scale production and robust ..
  16. Ross L Levine; Fiscal Year: 2016
    ..Recent studies have identified somatic mutations in known and putative epigenetic modifiers, including TET2, which encodes an enzyme which adds hydroxyl groups to 5-methylcytosine and leads to subsequent DNA hypomethylation...
  17. High Throughput Screen for JAK2V617F Mutant Selective Inhibitors
    Ross Levine; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  18. REGULATION OF INDUCIBLE NITRIC OXIDE SYNTHASE IN KIDNEY
    BRUCE KONE; Fiscal Year: 2002
    ....
  19. RASSF1 Tumor Suppressor Gene
    GERD PFEIFER; Fiscal Year: 2005
    ..The effect of RASSF1 expression on RAS signaling pathways will be studied. We will examine if RASSF1A, alone or in combination with activated RAS, induces cell death (apoptosis). ..
  20. DNA methylation in cancer genomes
    GERD PFEIFER; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  21. Regulation of H/K-ATPase in Kidney and Colon
    BRUCE KONE; Fiscal Year: 2009
    ..abstract_text> ..
  22. Postdoctoral Training in Renal Diseases and Hypertension
    BRUCE KONE; Fiscal Year: 2006
    ..It is the goal of the Program that its graduates will contribute to a new generation of academic nephrologists and renal investigators equipped to address the challenging problems in renal diseases and hypertension ..
  23. UV DAMAGE, REPAIR AND MUTAGENESIS
    GERD PFEIFER; Fiscal Year: 2003
    ..abstract_text> ..
  24. Characterization of MBD3L1 and MBD3L2
    GERD PFEIFER; Fiscal Year: 2008
    ..Since both proteins are likely functioning as transcriptional regulators, it will be important to determine if there are changes in gene expression patterns in Mbd311 and Mbd312 (-/-) cells. ..
  25. GENETIC TARGETING OF HEMATOPOIETIC STEM CELLS
    Timothy Graubert; Fiscal Year: 2002
    ..The long-term goal of this investigator is to study the molecular bases of hematopoiesis and leukemogenesis as an active member of a clinical Hematology/Bone Marrow Transplant Division. ..
  26. ACQUISTION OF A CYTOMATION MOFLO CELL SORTER
    Timothy Graubert; Fiscal Year: 2001
    ..An advisory committee will oversee management of the cell sorter and ensure its long-term stability as a resource for the medical school...
  27. Acquistion of an inFlux GMP cell sorter.
    Timothy Graubert; Fiscal Year: 2005
    ..This instrument will provide added value for many funded projects at Washington University that collectively accounted for over $328M in total awards from the NIH in 2002, placing it third among medical centers in the United States. ..
  28. INHIBITOR OF THE C ABL TYROSINE KINASE
    RICHARD VAN ETTEN; Fiscal Year: 2002
    ..These experiments will yield important new information about the function and regulation of c-Abl and the mode of activation of leukemogenic forms of Abl, and identify new avenues for anti-leukemic therapies. ..
  29. Novel Cellular Therapies for Ph+ leukemia
    RICHARD A contact VAN ETTEN; Fiscal Year: 2010
    ..PHS 398/2590 (Rev. 11/07) Page 2 Continuation Format Page Program Director/Principal Investigator (Last, First, Middle): Van Etten R.A./Klingemann H.K. ..
  30. Pathogenesis & Therapy of 8p11 Leukemia/Lymphoma
    RICHARD VAN ETTEN; Fiscal Year: 2008
    ..abstract_text> ..